-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the top academic journal "Science" published a research paper on the new coronavirus vaccine, providing new evidence for the vaccine booster to prevent the mutant new coronavirus
.
This preclinical study showed that six months after the macaque was vaccinated with the new crown vaccine mRNA-1273, the third dose of the mRNA vaccine can enhance the animal's antibody response, especially the neutralizing activity of the antibody against the mutant virus
This animal experiment was led by a research team from the National Institutes of Health (NIH) six months ago
.
At that time, the new crown mutant strain "Beta" was causing people's concerns
On the other hand, months have passed since several new crown vaccines were authorized for emergency use
.
For the first batch of people vaccinated, the neutralizing antibody in the body gradually weakened the response to the mutant strain
As new mutant virus strains continue to spread, is it necessary to inoculate booster shots? To answer this question, the researchers evaluated the immune response of non-human primates
.
Six months after the experimental macaques received two doses of mRNA-1273 vaccine, the researchers injected them with two booster shots
Experimental results show that the two booster needles can enhance the antibody response equally effectively, and the vaccine-induced neutralizing antibodies lasted for at least 8 weeks
.
Nine weeks after the third injection, the researchers conducted a challenge experiment with the beta strain
.
The results showed that the reinforced needle produced a high level of protection
The researchers concluded that these experimental results support the promotion of vaccines among high-risk groups-the elderly, people with congenital health problems, high-risk contacts, and people who have not responded well to the original vaccination to reduce the possibility of infection and transmission
Reference materials:
[1] Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates.
[2] COVID vaccine booster increases antibody responses, is protective in rhesus macaques.
